Prostate Cancer Promotes CD11b Positive Cells to Differentiate Into Osteoclasts

Bone is the preferred site of prostate cancer metastasis, contributing to the morbidity and mortality or this disease. A key step in the successful establishment of prostate cancer bone metastases is activation of osteoclasts with subsequent bone resorption causing the release of several growth factors from the bone matrix. CD11b+ cells in bone marrow are enriched for osteoclast precursors. Conditioned media from prostate cancer PC-3 cells induces CD11b+ cells front human peripheral blood to differentiate into functional osteoclasts with subsequent bone resorption. Analysis or PC-3 conditioned media revealed high amounts of IL-6 and IL-8. CD11b+ cells were cultured with M-CSF and RANKL, IL-6, IL-8, and CCL2, alone or in combination. All of these conditions induced osteoclast fusion, but cells cultured with M-CSF, IL-6, IL-8, and CCL2 were capable of limited bone resorption. Co-incubation with IL-6 and IL-8 and the RANK inhibitor, RANK-Fc, failed to inhibit osteoclast fusion and bone resorption, suggesting a potential RANKL-in dependent mechanism of functional osteoclast formation. This study demonstrates that functional osteoclasts can be derived from CD11b+ cells derived from human PBMCs. Prostate cancer cells secrete factor, including IL-6 and IL-8, that play an important role in osteoclast fusion by a RANKL-independent mechanism. J. Cell. Biochem. 106: 561-569, 2009. (C) 2009 Wiley-Liss, Inc.